# 20/20 GeneSystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/20-20-genesystems

- Industry: Healthcare
- Headquarters: Rockville, US
- Website: www.2020gene.com
- Latest round: Series B (Nov 1, 2018)
- Investors on record: 1

## About

20/20 GeneSystems Inc. specializes in AI-powered blood tests for early cancer detection and chronic disease prevention, offering innovative solutions that enhance healthcare accessibility and comfort.20/20 GeneSystems Inc. focuses on developing advanced diagnostic solutions. Founded in 2000 in Rockville, US, the company has successfully completed 7 deals, with its most recent funding round being a Series A in April 2019, raising USD 23.00 mn, which is also the total amount raised.20/20 BioLabs offers a suite of advanced, AI-powered laboratory-based blood tests for early cancer detection and prevention of chronic diseases. Their core product, OneTest™, uses a unique protein tumor marker approach to detect multiple cancers, including lung, pancreatic, ovarian, and liver cancers, at treatable stages. The tests facilitate at-home collection using painless capillary blood devices, addressing accessibility and comfort. Additionally, the company is set to launch a new test measuring inflammation biomarkers related to chronic diseases like heart disease, diabetes, and mental health disorders, anticipated for release in Spring.20/20 BioLabs generates revenue through direct-to-consumer sales of its diagnostic tests, with OneTest™ priced at under USD 200, significantly lower than competing tests that exceed USD 1,000. Sales occur primarily online, supported by a user-friendly platform. The company also engages in partnerships with healthcare providers for bulk testing, broadening its client base. As a CAP Accredited and CLIA Licensed laboratory, 20/20 BioLabs ensures high standards of accuracy and reliability, fostering customer trust and repeat business.20/20 GeneSystems Inc. is focusing on launching new products, including a test for inflammation biomarkers, expected in Spring. The company plans to expand its reach into international markets, although specific locations have not been disclosed. The USD 23.00 mn raised in the recent Series A funding round will support these initiatives, allowing for increased product development and market expansion.

## Funding rounds

- Series B, Nov 1, 2018 — DigitalDx Ventures

## Investors

- DigitalDx Ventures (https://capitalatlas.ai/funds/digitaldx-ventures) — Series B